142 related articles for article (PubMed ID: 30998516)
21. Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis.
Saha S; Mazumdar T; Anam K; Ravindran R; Bairagi B; Saha B; Goswami R; Pramanik N; Guha SK; Kar S; Banerjee D; Ali N
J Clin Microbiol; 2005 Mar; 43(3):1269-77. PubMed ID: 15750095
[TBL] [Abstract][Full Text] [Related]
22. Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies.
Mondal D; Bern C; Ghosh D; Rashid M; Molina R; Chowdhury R; Nath R; Ghosh P; Chapman LAC; Alim A; Bilbe G; Alvar J
Clin Infect Dis; 2019 Jul; 69(2):251-258. PubMed ID: 30357373
[TBL] [Abstract][Full Text] [Related]
23. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
24. Foxp3 and IL-10 expression correlates with parasite burden in lesional tissues of post kala azar dermal leishmaniasis (PKDL) patients.
Katara GK; Ansari NA; Verma S; Ramesh V; Salotra P
PLoS Negl Trop Dis; 2011; 5(5):e1171. PubMed ID: 21655313
[TBL] [Abstract][Full Text] [Related]
25. Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile.
Ismail A; El Hassan AM; Kemp K; Gasim S; Kadaru AE; Moller T; Kharazmi A; Theander TG
J Pathol; 1999 Dec; 189(4):615-22. PubMed ID: 10629566
[TBL] [Abstract][Full Text] [Related]
26. The immunology of post-kala-azar dermal leishmaniasis (PKDL).
Zijlstra EE
Parasit Vectors; 2016 Aug; 9(1):464. PubMed ID: 27553063
[TBL] [Abstract][Full Text] [Related]
27. The importance of T cell-derived cytokines in post-kala-azar dermal leishmaniasis.
Jafarzadeh A; Jafarzadeh S; Sharifi I; Aminizadeh N; Nozari P; Nemati M
Cytokine; 2021 Nov; 147():155321. PubMed ID: 33039255
[TBL] [Abstract][Full Text] [Related]
28. Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis.
Zijlstra EE; el-Hassan AM; Ismael A
Am J Trop Med Hyg; 1995 Apr; 52(4):299-305. PubMed ID: 7741164
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of a rapid immunochromatographic test for diagnosis of kala-azar & post kala-azar dermal leishmaniasis at a tertiary care centre of north India.
Mathur P; Samantaray J; Chauhan NK
Indian J Med Res; 2005 Dec; 122(6):485-90. PubMed ID: 16517998
[TBL] [Abstract][Full Text] [Related]
30. Challenges in the diagnosis of post kala-azar dermal leishmaniasis.
Salotra P; Singh R
Indian J Med Res; 2006 Mar; 123(3):295-310. PubMed ID: 16778312
[TBL] [Abstract][Full Text] [Related]
31. Interferon (IFN)-gamma , tumor necrosis factor-alpha , interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis.
Ansari NA; Ramesh V; Salotra P
J Infect Dis; 2006 Oct; 194(7):958-65. PubMed ID: 16960784
[TBL] [Abstract][Full Text] [Related]
32. Real-Time Fluorimetry Loop-Mediated Isothermal Amplification for Diagnosis of Leishmaniasis and as a Tool for Assessment of Cure for Post-Kala-Azar Dermal Leishmaniasis.
Dixit KK; Ramesh V; Gupta R; Negi NS; Singh R; Salotra P
Am J Trop Med Hyg; 2021 Apr; 104(6):2097-2107. PubMed ID: 33872204
[TBL] [Abstract][Full Text] [Related]
33. Visceral Leishmaniasis IgG1 Rapid Monitoring of Cure vs. Relapse, and Potential for Diagnosis of Post Kala-Azar Dermal Leishmaniasis.
Marlais T; Bhattacharyya T; Singh OP; Mertens P; Gilleman Q; Thunissen C; Hinckel BCB; Pearson C; Gardner BL; Airs S; de la Roche M; Hayes K; Hafezi H; Falconar AK; Eisa O; Saad A; Khanal B; Bhattarai NR; Rijal S; Boelaert M; El-Safi S; Sundar S; Miles MA
Front Cell Infect Microbiol; 2018; 8():427. PubMed ID: 30619774
[No Abstract] [Full Text] [Related]
34. Liposomal amphotericin B is more effective in polymorphic lesions of post kala-azar dermal leishmaniasis.
Moulik S; Sengupta R; Ghosh MK; Das NK; Saha B; Chatterjee M
Indian J Dermatol Venereol Leprol; 2022; 88(2):201-206. PubMed ID: 33969651
[TBL] [Abstract][Full Text] [Related]
35. PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: review of clinical presentation in relation to immune responses.
Zijlstra EE
PLoS Negl Trop Dis; 2014; 8(11):e3258. PubMed ID: 25412435
[TBL] [Abstract][Full Text] [Related]
36. High levels of C-reactive protein in the peripheral blood during visceral leishmaniasis predict subsequent development of post kala-azar dermal leishmaniasis.
Gasim S; Theander TG; ElHassan AM
Acta Trop; 2000 Feb; 75(1):35-8. PubMed ID: 10708005
[TBL] [Abstract][Full Text] [Related]
37. Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis.
Singh R; Kumar D; Ramesh V; Negi NS; Singh S; Salotra P
J Infect Dis; 2006 Aug; 194(3):302-6. PubMed ID: 16826477
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
Musa AM; Khalil EA; Mahgoub FA; Hamad S; Elkadaru AM; El Hassan AM
Ann Trop Med Parasitol; 2005 Sep; 99(6):563-9. PubMed ID: 16156969
[TBL] [Abstract][Full Text] [Related]
39. Does immune dysregulation contribute towards development of hypopigmentation in Indian post kala-azar dermal leishmaniasis?
Sengupta R; Mitra S; Dighal A; Moulik S; Chaudhuri SJ; Das NK; Chatterjee U; Chatterjee M
Exp Dermatol; 2023 Jun; 32(6):740-751. PubMed ID: 36760064
[TBL] [Abstract][Full Text] [Related]
40. Identification and glycobiological characterization of circulating immune complexes in patients with visceral leishmaniasis and post kala azar dermal leishmaniasis.
Datta S; Modak D; Sarkar S; Saha B; Mukhopadhyay S
Indian J Exp Biol; 2015 Jun; 53(6):321-8. PubMed ID: 26155670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
